In a multicenter, randomized trial, the SGLT2 inhibitor dapagliflozin improved the health status and exercise function of patients with heart failure with preserved ejection fraction (HFpEF), a condition for which effective treatments are lacking.
- Michael E. Nassif
- Sheryl L. Windsor
- Mikhail N. Kosiborod